Eli Lilly Says Verzenio Reduced Risk of Death In Late-Stage Trial In Some Breast Cancer Patients

Eli Lilly and Company (LLY) on Friday stated that two years of adjuvant Verzenio plus endocrine therapy reduced the risk of death by 15.8% as compared to endocrine therapy alone in a late-stage trial in patients with a certain type of high-risk early breast cancer.

According to the firm, Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in this type of breast cancer.

Furthermore, treatment with Verzenio plus endocrine therapy led to a sustained reduction in risk of recurrence at seven years, Lilly said. The company noted that 32% fewer patients treated with Verzenio plus ET were living with metastatic disease compared to those receiving ET alone after seven years.

“Continued long-term follow-up from this trial will help to determine whether this ongoing difference in patients alive with metastatic disease translates into further deepening of survival benefit with time,” the company said.

The data is being submitted to health authorities worldwide, the company said. Jacob Van Naarden, executive vice president and president of Lilly Oncology, termed the study results an “important advancement” in the care of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer.

Safety findings were consistent with the known profile of Verzenio, and adverse events were generally managed with dose modifications in the study, the company added.

LLY shares traded 4% lower in the pre-market session at the time of writing after President Trump said on Thursday that the price of its rival Novo Nordisk’s weight-loss drug would be lowered. On Stocktwits, retail sentiment around LLY stock stayed within the ‘bearish’ territory while message volume rose from ‘low’ to ‘high’ levels.

LLY stock is up by 6% this year but has fallen 11% over the past 12 months. 

Read also: Protalix BioTherapeutics Stock Tumbled 28% Today: Why The Latest CHMP Opinion Is Sparking Concerns Among Investors?

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share

·

Add us on